Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant/Metformin Combinations in Type 2 Diabetes
NCT00754689Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- Sep 2008
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in Glycosylated Hemoglobin 1c at 9 months. Planned start Sep 2008; status: withdrawn.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00754689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00754689.